Strong Momentum Drives New High
On 24 Dec 2025, Venus Remedies touched an intraday peak of Rs.848.9, representing its highest price level in the past year and an all-time high for the company. This milestone comes amid a four-day consecutive gain period, during which the stock has delivered a cumulative return of 11.67%. The day’s trading session saw the stock outperform its sector by 2.3%, reflecting robust investor interest and positive market dynamics within the Pharmaceuticals & Biotechnology space.
The stock’s current price level is well above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum and technical strength. This alignment of moving averages often indicates a bullish trend, reinforcing the stock’s recent performance trajectory.
Market Context and Sector Performance
The broader market environment has also been supportive. The Sensex opened flat but gradually moved into positive territory, trading at 85,599.96 points, a mere 0.65% below its own 52-week high of 86,159.02. The index’s position above its 50-day moving average, which itself is above the 200-day moving average, suggests a generally bullish market sentiment. Additionally, small-cap stocks led the market gains, with the BSE Small Cap index rising by 0.33% on the day, highlighting a favourable backdrop for mid and small-cap stocks like Venus Remedies.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Year-on-Year Performance Highlights
Venus Remedies has demonstrated remarkable performance over the past year, with a return of 176.04% compared to the Sensex’s 9.09% during the same period. The stock’s 52-week low was Rs.272.2, illustrating a significant price appreciation over the last twelve months. This substantial price movement reflects the company’s strong financial results and market positioning.
Profitability metrics have shown notable changes, with the company’s net profit growing by 473.5% in the most recent quarter, reaching Rs.20.13 crores. This growth has been consistent, with positive results declared for four consecutive quarters. The return on capital employed (ROCE) for the half-year period stands at 13.99%, while the return on equity (ROE) is recorded at 10.5%, indicating efficient utilisation of capital and shareholder funds.
Inventory turnover ratio for the half-year is at 6.58 times, suggesting effective inventory management relative to sales. The company’s debt-to-equity ratio remains low, averaging zero, which points to a conservative capital structure with minimal reliance on debt financing.
Valuation and Market Positioning
Venus Remedies is trading at a price-to-book value of 1.8, which is considered attractive when compared to its peers’ historical valuations. The company’s price-to-earnings growth (PEG) ratio is 0.1, reflecting the relationship between its price, earnings, and growth rate. These valuation metrics suggest that the stock is trading at a fair value relative to its financial performance and growth prospects.
Over the longer term, Venus Remedies has outperformed the BSE500 index across multiple time frames, including the last three years, one year, and three months. This consistent outperformance highlights the company’s ability to generate market-beating returns over both short and extended periods.
Thinking about Venus Remedies ? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Considerations on Market Participation
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect a cautious stance or differing assessment of the stock’s valuation or business fundamentals. Such a scenario is not uncommon for companies in the mid and small-cap segments, where institutional ownership can vary significantly.
Nonetheless, Venus Remedies’ recent price action and financial metrics indicate a period of strong market momentum and operational strength, as evidenced by its new 52-week high and consistent quarterly results.
Summary
Venus Remedies’ achievement of a new 52-week high at Rs.848.9 marks a significant milestone for the company within the Pharmaceuticals & Biotechnology sector. Supported by strong quarterly profits, attractive valuation metrics, and positive technical indicators, the stock has demonstrated robust momentum over recent sessions. The broader market environment, with the Sensex trading near its own 52-week high and small caps leading gains, provides a conducive backdrop for Venus Remedies’ continued market presence at elevated price levels.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Start Saving Now →
